Company Overview - Repligen (RGEN) shares increased by 3.7% to $174.24 in the last trading session, with a notable trading volume indicating strong investor interest [1] - The company specializes in advanced bioprocessing technologies and solutions for large biopharmaceutical companies and contract manufacturing organizations [2] Financial Performance - Repligen is expected to report quarterly earnings of $0.41 per share, reflecting a year-over-year increase of 24.2% [3] - Revenue projections for the upcoming quarter stand at $167.72 million, which is a 7.7% increase compared to the same quarter last year [3] - However, the consensus EPS estimate has been revised down by 1.3% over the last 30 days, which may impact future stock price appreciation [4] Industry Context - Repligen is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Exelixis (EXEL), experienced a 0.4% decline in its last trading session [4] - Exelixis has a consensus EPS estimate of $0.50, representing a significant year-over-year change of 51.5% [5]

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible through Repl ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in co ...

It has been about a month since the last earnings report for Repligen (RGEN) . Shares have added about 3.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Repligen’s Q3 Earnings & Revenues Surpass EstimatesRe ...

Core Insights - Repligen Corporation has published its 2023 Corporate Sustainability Report themed "Advancing Impacts," highlighting progress in sustainability across six key areas [1][2] - The report includes disclosures aligned with major reporting frameworks such as GRI, SASB, UN SDGs, and TCFD [1] Sustainability Highlights - Transitioned to 100% renewable electricity at 13 out of 18 manufacturing sites, accounting for 88% of global consumption [3] - Increased the percentage of women in management roles from 27% in 2022 to 29% in 2023 [3] - Achieved a 68% reduction in Scope 2 emissions from 2022 to 2023 [3] - Realized a 60% increase in productivity savings through the Repligen Performance System compared to 2022 [3] - Committed to achieving net-zero emissions by 2050 in alignment with the Science Based Targets initiative [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Othe ...

Repligen Corporation (NASDAQ:RGEN) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital ...

Repligen Corporation (RGEN) reported third-quarter 2024 adjusted earnings per share of 43 cents, which beat the Zacks Consensus Estimate of 34 cents. The company recorded adjusted earnings of 23 cents per share in the year-ago quarter.Total revenues were $154.9 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 7% organically. The reported figure also beat the Zacks Consensus Estimate of $153.1 million.This increase in total ...

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million.Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and ...

Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this drug developer would post earnings of $0.33 per share when it actually produced earnings of $0.33, delivering no surprise.Over the last four quarters, the company has surpa ...